LUN and HLUNB Related Headlines
Go Back- European Commission grants orphan designation for Lundbeck's investigational anti-ACTH monoclonal antibody asedebart for Cushing's syndrome of endogenous origin
- Lundbeck to present new patient data on neuroendocrine and neuroimmunology programs at ENDO 2026
- Lundbeck presents positive Phase IIb data for bocunebart (Lu AG09222; anti-PACAP mAb) in migraine prevention at the AHS congress
- Lundbeck presents Phase 1b data for Parkinson's drug at conference
- Lundbeck advances Parkinson's research with new Phase 1b data at AD/PD™ 2026
- Lundbeck to present comprehensive new bexicaserin dataset in patients with rare childhood-onset epilepsies, at American Epilepsy Society (AES) Annual Meeting
LUN and HLUNB Related Press Releases
Go Back- European Commission grants orphan designation for Lundbeck's investigational anti-ACTH monoclonal antibody asedebart for Cushing's syndrome of endogenous origin
- Lundbeck to present new patient data on neuroendocrine and neuroimmunology programs at ENDO 2026
- Lundbeck presents positive Phase IIb data for bocunebart (Lu AG09222; anti-PACAP mAb) in migraine prevention at the AHS congress
- Lundbeck advances Parkinson's research with new Phase 1b data at AD/PD™ 2026
- Lundbeck to present comprehensive new bexicaserin dataset in patients with rare childhood-onset epilepsies, at American Epilepsy Society (AES) Annual Meeting
